Comparison of safety and efficacy of fluorouracil plus oxaliplatin plus irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice-MedSci.cn

Comparison of safety and efficacy of fluorouracil plus oxaliplatin plus irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice

Kazama, K; Shiozawa, M; Numata, M; Sugano, N; Sato, S; Uchiyama, M; Sato, M; Aoyama, T; Tamagawa, H; Oshima, T; Yukawa, N; Rino, Y

Kazama, K (通讯作者)，Kanagawa Canc Ctr, Dept Gastrointestinal Surg, Yokohama, Kanagawa, Japan.;Kazama, K (通讯作者)，Yokohama City Univ, Dept Surg, Kanazawa Ku, 3-9 Fukuura, Yokohama, Kanagawa 2360004, Japan.

Abstract

Purpose The efficacy of fluorouracil + oxaliplatin + irinotecan with bevacizumab (FOLFOXIRI + BV) has been verified for metastatic colorectal cancer (......

Full Text Link

Links

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

Comparison of safety and efficacy of fluorouracil plus oxaliplatin plus irinotecan (FOLFOXIRI) and modified FOLFOXIRI with bevacizumab for metastatic colorectal cancer: data from clinical practice

科室

工具

服务